SCHEMBL4075856

SCHEMBL4075856

Cc1cccc2cc(CN(C3CCC3)S(=O)(=O)c3ccc4c(c3)OCCN4C)c(=O)[nH]c12

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 9/20 0.53
ALDH1A1 P00352 9/20 0.53
KDM4E B2RXH2 9/20 0.53
LMNA P02545 3/20 0.53
MAPK1 P28482 3/20 0.53
MAPT P10636 2/20 0.53
HTT P42858 1/20 0.46
HPGD P15428 2/20 0.45
ATM Q13315 1/20 0.44
TSHR P16473 5/20 0.43
USP2 O75604 2/20 0.42
KMT2A Q03164 2/20 0.42
APOBEC3A P31941 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
MEN1 O00255 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4076735 0.99 HSD17B10 (0.52) HSD17B10ALDH1A1KDM4ELMNAMAPK1
SCHEMBL4073661 0.98 HSD17B10 (0.51) HSD17B10ALDH1A1KDM4ELMNAMAPK1
SCHEMBL4075211 0.98 HSD17B10 (0.53) HSD17B10ALDH1A1KDM4ELMNAMAPK1
SCHEMBL4070864 0.95 HSD17B10 (0.51) HSD17B10ALDH1A1KDM4ELMNAMAPK1
SCHEMBL4073862 0.95 ALDH1A1 (0.51) HSD17B10ALDH1A1KDM4ELMNAMAPK1
SCHEMBL4075922 0.94 KDM4E (0.50) HSD17B10ALDH1A1KDM4ELMNAMAPK1
SCHEMBL4075919 0.94 KDM4E (0.50) HSD17B10ALDH1A1KDM4ELMNAMAPK1
SCHEMBL4076729 0.91 ALDH1A1 (0.49) HSD17B10ALDH1A1KDM4ELMNAMAPK1
SCHEMBL4076730 0.91 ALDH1A1 (0.49) HSD17B10ALDH1A1KDM4ELMNAMAPK1
SCHEMBL4076728 0.91 ALDH1A1 (0.49) HSD17B10ALDH1A1KDM4ELMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP claimed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US claimed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO claimed
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP disclosed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US disclosed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof ABCG2, ATP5ME, ATP5MG HSD17B10 1580/4885ALDH1A1 1055/4885KDM4E 2403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.